Turn Your GLP-1 Patients
Into the Real-World Evidence
Your Pipeline Needs.
30–50% of GLP-1 patients discontinue within six months. Every one of them is a lost outcome, a lost data point, and a lost story. SureMediks closes the gap between visits — extending adherence, capturing real-world evidence, and giving your medical affairs and commercial teams the longitudinal patient journey your clinical trials never could.
standard of care
RWE asset
25–40% of GLP-1 Weight Loss Can Be Muscle. The Brand That Captures & Preserves It Wins the Long Game.
Body-composition outcomes — including direct fat-metabolism data — are the next frontier of GLP-1 differentiation. Pharma medical affairs teams know it. Payers are starting to ask about it. Most patient support programmes can't capture either signal at scale. SureMediks turns the lean-mass and fat-metabolism questions from clinical concerns into a publishable, payer-ready evidence asset for your therapy.
SureMediks generates the dataset clinical trials cannot: weekly body composition (weight, body-fat percentage, lean muscle) plus on-demand BHB ketone readings — the only direct circulating biomarker for fat metabolism. Together, these turn your therapy's body-composition story from inferred to measured.
- Weekly lean mass trajectories across thousands of patients on your therapy
- BHB ketone data — direct evidence of fat metabolism your trials never captured at this scale
- Comparative body composition cohorts against historical or competitor benchmarks
- Sub-population analyses — older patients, perimenopausal women, frail and at-risk groups
- Publication-ready datasets for medical affairs, advisory boards, and payer evidence
GLP-1 patients eat dramatically less. The SureMediks nutrition manager actively preserves muscle and engagement — turning your therapy from a weight-loss intervention into a coordinated body-composition outcome.
- Protein targets at 1.2–1.6 g/kg ideal body weight — the clinical lever for muscle preservation
- Daily intake tracking with structured PRO capture
- Provider-coded meal protocols aligned to your therapy's profile
- Hydration and electrolyte data across the GI tolerance window
- Engagement and adherence signals that strengthen your real-world outcomes story
See Exactly How SureMediks Extends Your Therapy.
Click any phase below to see the modules, the data captured, and what Realistic Intelligence® does — through whichever lens matters to your team.
Without SureMediks: she silently discontinues by Day 21. She tells her friends the medication "didn't work for her." Her data never enters your post-marketing dataset. She becomes part of the 30–50% statistic that follows your therapy in every market access conversation.
With SureMediks: her tolerance signal routes through Realistic Intelligence®, the coach gets the alert within hours, the dose is paused and a hydration protocol is delivered through the patient app. By Day 25 she's titrating again. She stays on therapy through month 6, month 12, month 18 — generating the kind of longitudinal real-world evidence your medical affairs team can publish, your commercial team can cite, and your HEOR team can present to payers.
This is what "extending therapy beyond the prescription" actually looks like.
More Than a Patient Support
Programme. A Real-World
Evidence Engine.
Most pharma-funded support programmes are call centres with apps bolted on. SureMediks is a clinical-grade platform that extends your therapy, captures the data your pipeline needs, and meets the regulatory bar your medical affairs team requires.
- White-label deployment under your brand or co-branded
- 21 CFR Part 11 and GxP-aligned data capture
- Validated patient-reported outcomes (PROs) at scale
- Realistic Intelligence® — provider-coded protocols, not generic AI
- Continuous longitudinal data — adherence, weight, comorbidities, PROs
- Publication-ready datasets for medical affairs and HEOR
- Privacy-first architecture · HIPAA · patient-consented
Let's Map This Onto Your Therapy.
A 30-minute partnership call to map this six-phase walkthrough onto your therapy, your indication, your medical affairs strategy and your real-world evidence priorities. No pitch deck. A conversation between people who care about extending therapy beyond the prescription.